Copy For Citation
Tat T. S., ÇİLLİ A.
ISTANBUL MEDICAL JOURNAL, vol.18, no.3, pp.135-138, 2017 (ESCI)
-
Publication Type:
Article / Article
-
Volume:
18
Issue:
3
-
Publication Date:
2017
-
Doi Number:
10.5152/imj.2017.93653
-
Journal Name:
ISTANBUL MEDICAL JOURNAL
-
Journal Indexes:
Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
-
Page Numbers:
pp.135-138
-
Keywords:
Asthma, omalizumab, severe allergic asthma, uncontrolled allergic asthma, QUALITY-OF-LIFE, REAL-LIFE, ANTIBODY OMALIZUMAB, MODERATE, TOLERABILITY, MALIGNANCY, EFFICACY, THERAPY, SAFETY
-
Akdeniz University Affiliated:
Yes
Abstract
Introduction: Omalizumab is a monoclonal antibody used for treating patients with severe allergic asthma. It has has been shown to be effective and is being increasingly used. This study aimed to evaluate the long-term efficacy and safety of omalizumab treatment in patients with severe allergic asthma.